Compare DexCom, Inc. (DXCM) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.85 (market cap $17.53B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| DXCM | USIG | |
|---|---|---|
Market Cap | $31.86B | $17.53B |
Volume | 3,607,070 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $92.34 | $52.69 |
52-Week Low | $54.84 | $48.54 |
Typical Hold Time | 62 Days | 44 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
USIG trades at $48.68 with minimal daily movement (+0.06%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces resistance at $49 with support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9% in Q2 2026.
The outlook remains cautious due to bearish technicals and lack of fundamental data. Investment opportunities include institutional accumulation, but risks involve market volatility and absence of recent financial disclosures. Investors should await updated earnings reports for clearer valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
